Hemorrhoid Treatment Market Supported by E-commerce Distribution Channels

1. Hemorrhoid Treatment Market Size, Share & Global Growth Forecast to 2032 The hemorrhoid treatment market is witnessing steady growth due to the rising prevalence of hemorrhoids globally, especially among aging populations and individuals with sedentary lifestyles. Treatment options range from over-the-counter creams and medications to minimally invasive procedures like rubber band ligation, sclerotherapy, and surgical interventions. Increasing awareness about gastrointestinal health, advancements in treatment technologies, and improved healthcare access are key drivers of market growth. As lifestyle-related health issues become more common, the demand for effective and accessible hemorrhoid treatments continues to rise worldwide. According to Fortune Business Insights, the global hemorrhoid treatment market was valued at USD 1.03 billion in 2023. The market is projected to grow from USD 1.08 billion in 2024 to USD 1.74 billion by 2032, exhibiting a CAGR of 6.1% during the forecast period. In 2023, North America dominated the hemorrhoid treatment market with a market share of 44.66%. Leading Companies in the Market           Lupin (India) Cipla (India) AMATO PHARMACEUTICAL PRODUCTS, LTD. (Japan) Church & Dwight Co., Inc. (U.S.) Haleon Group of Companies (U.K.) Sebela Pharmaceuticals (U.S.) Bayer AG (Germany) Sanofi (France) Abbott (U.S.) Sun Pharmaceutical Industries, Inc. (India) Key Industry Development In September 2024, the U.K.-based Haleon Group acquired Tianjin TSKF Pharmaceutical Co. Ltd, China. This strategic move strengthens its position in the hemorrhoid treatment market by enhancing product control and operational agility. Market Drivers & Restraints Market Drivers  High Prevalence of Hemorrhoids: With an estimated global prevalence rate of approximately 4.4%—and up to 60–70% lifetime incidence in North America—hemorrhoids are a common ailment worldwide. Easy OTC Access: Widespread availability of OTC treatments, such as creams, ointments, suppositories, and sprays, allows patients to self-manage symptoms conveniently, bypassing social barriers to seeking doctor consultations.  Market Restraints

2.  Social Stigma: Embarrassment about hemorrhoids prevents many individuals from seeking medical attention, impacting diagnosis and advanced treatment uptake. Alternative Treatments: Non-pharmacological options like stool softeners, band ligation, infrared coagulation, and sclerotherapy offer cost-effective alternatives and may curb market growth. Regulatory Complexity: The lack of FDA-approved pharmaceutical products and stringent regulatory requirements delay new product introductions.   Market Report Coverage The report spans detailed segmentation across product types, drug classes, hemorrhoid types, and distribution channels. It outlines regional forecasts, reviews competitive dynamics, evaluates COVID-19 impacts on symptom incidence, and examines economic implications of untreated hemorrhoids. Competitive Landscape Market competition is intense, with leading brands like Haleon, Church & Dwight, Bayer, and Lupin backing expansive OTC and prescription portfolios. Notably, Church & Dwight renewed a partnership in February 2024 to enhance distribution of its Anusol range in Hong Kong, reinforcing its market presence. Market Segments By Product Type  Creams & Ointments: Leading product segment thanks to user preference for non-invasive, easy- to-use formulations. Suppositories: Popular for internal hemorrhoids—especially grades I and II. Sprays & Others: Gaining traction for convenience and fast-acting relief.  

3. By Drug Class  Corticosteroids: Top-selling class, with hydrocortisone-based creams offering anti-inflammatory and anti-itch relief. Local Anesthetics (e.g., lidocaine): Widely used for temporary pain relief. NSAIDs and Others: Includes pain relievers, stool softeners, and combinations for multi-symptom control.   By Type  Internal Hemorrhoids: Largest share due to high grade I–IV prevalence. A 2020 study in Ethiopia found ~13.1% prevalence, with grade I representing 64% of cases. External Hemorrhoids: Also growing driven by increased OTC product availability  By Distribution Channel  Drug Stores & Retail Pharmacies: Dominant channel due to OTC availability and consumers’ preference for privacy. Hospital Pharmacies: Serve post-diagnosis prescription needs. Online Pharmacies: Fastest-growing channel, offering discreet access and telemedicine integration.   Regional Insights North America:Largest market (44.66 % share; USD 0.46 billion in 2023) due to high incidence and advanced healthcare systems. Europe: Strong growth supported by regulatory frameworks and public health initiatives, with Germany treating ~3.3 million hemorrhoid patients annually. Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/hemorrhoid-treatment-market-110985 Emerging Trends & Opportunities  Pipeline Innovation: Companies such as Citius Pharmaceuticals have advanced topical treatments (e.g., Halo-Lido) through Phase 2b trials. Convenient Formulations:Preparations like Haleon’s Preparation H Totables wipes are gaining traction for rapid relief. Telemedicine Integration: At-home OTC use supported by digital consultation services presents growth opportunities.   Future Market Scope Looking ahead, the hemorrhoid treatment market is set for sustained growth. Increased R&D for targeted non-invasive therapies, integration of telehealth, and expansion of discreet digital sales models will guide market evolution. Stakeholder strategies should focus on consumer-centric solutions, destigmatization efforts, and affordable access. About Us: Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them

4. address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in. Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data. At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges. Contact us: Fortune Business Insights™ Pvt. Phone: USA: +1 833 909 2966 (Toll-Free), United Kingdom: +44 808 502 0280 (Toll-Free), APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com